Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis

BMJ, 12 May 2015

This paper aims to assess the reduction in the vaccine preventable burden of cancer in men if boys are vaccinated along with girls against oncogenic human papillomavirus (HPV) using a Bayesian evidence synthesis approach to evaluate the impact of vaccination against HPV types 16 and 18 on the burden of anal, penile, and oropharyngeal carcinomas among heterosexual men and men who have sex with men.

Click here to access the full text.

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

BMJ, 7 January 2015

This study investigates the incremental cost effectiveness of two dose human papillomavirus vaccination and of additionally giving a third dose.

The results show that giving at least two doses of vaccine seems to be highly cost effective across the entire range of scenarios considered at the quadrivalent vaccine list price of £86.50 (€109.23; $136.00) per dose. If two doses give only 10 years’ protection but adding a third dose extends this to lifetime protection, then the third dose also seems to be cost effective at £86.50 per dose (median incremental cost effectiveness ratio £17 000, interquartile range £11 700-£25 800). If two doses protect for more than 20 years, then the third dose will have to be priced substantially lower (median threshold price £31, interquartile range £28-£35) to be cost effective. Results are similar for a bivalent vaccine priced at £80.50 per dose and when the same scenarios are explored by parameterising a Canadian model (HPV-ADVISE) with economic data from the United Kingdom.

The study concludes that two dose human papillomavirus vaccine schedules are likely to be the most cost effective option provided protection lasts for at least 20 years. As the precise duration of two dose schedules may not be known for decades, cohorts given two doses should be closely monitored.

Click here to access the full text article.  You will need to login with your Athens password to view this article.

All Lancashire Care staff are eligble to register for an Athens password.  Please click here to register for an Athens password.

Reducing the spread of hepatitis B

NICE, 28 July 2014

NICE’s quality standard for hepatitis B can help to reduce the spread of the infection by ensuring that people who are at increased risk are offered testing and vaccination. Testing should be offered in a range of settings such as at GP practices, prisons, drug services, and sexual health and genitourinary medicine clinics.

Click here to read more.

Parents who refuse vitamin K for newborns are also likely to refuse vaccinations, Canadian study finds

The British Medical Journal, 21 August 2014

Parents who declined vitamin K prophylaxis for their newborns were more likely to have had their child at home, to have had the child delivered by a midwife, and subsequently to decline to have their children vaccinated, a Canadian study has found…

Click here to view the full text.  You will need to login with your Athens password to view this article.  

All Lancashire Care staff are able to register for an Athens password.  Please click here to apply for an Athens password.